In this study, nafithromycin caused inhibition of pro-inflammatory markers such as myeloperoxidase (MPO), TNF-α and IL-6, which may provide additional clinical benefits by resolving the secondary complications associated with severe pneumonia.16 This evidence concerns the gene MPO and susceptibility to pneumonia measurement.